Skip to content
ClinCalc Pro
Menu
Intranasal Corticosteroid

Mometasone Nasal Spray

Brand names: Nasonex, Clarinaze (with loratadine)

Mometasone furoate nasal spray is an intranasal corticosteroid used for allergic rhinitis and as a component of nasal polyp management, delivering anti-inflammatory steroid directly to the nasal mucosa with minimal systemic exposure.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Mometasone is a potent topical glucocorticoid that acts on nasal mucosal cells to suppress inflammatory mediator release and reduce mucosal oedema, easing congestion, rhinorrhoea and sneezing.

Prescribing in practice

  • Correct technique — aiming the spray away from the nasal septum — reduces the risk of epistaxis, nasal irritation and, rarely, septal perforation with prolonged use.
  • Full benefit develops over days of regular use, so it should be taken continuously rather than as required during the relevant season.
  • Long-term use, particularly alongside inhaled or other corticosteroids, warrants awareness of cumulative steroid load and, in children, periodic height monitoring.

Monitoring

Periodically check inhalation/intranasal technique and inspect for nasal irritation or bleeding, and monitor growth in children on prolonged treatment.

Counselling the patient

  • Use it every day as prescribed; it may take several days to work fully.
  • Aim the nozzle slightly outward, away from the middle wall of the nose, to reduce nosebleeds.
  • Tell your clinician about persistent nosebleeds, crusting or a whistling sound when breathing.

Evidence & guidelines

Intranasal mometasone is a guideline-recommended first-line treatment for moderate-to-severe allergic rhinitis and is established in nasal polyp care, supported by NICE and the SPC.

Reference: NICE NG174; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.